[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351114-105":59,"doc-detail-351114-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeted-paclitaxel-delivery-in-ovarian-cancer-via-ap1-functionalized-elastin-like-polypeptide-nanocarriers-development-and-characterization","Targeted paclitaxel delivery in ovarian cancer via AP1-functionalized elastin-like polypeptide nanocarriers - development and characterization","","Paclitaxel has been a cornerstone of ovarian cancer chemotherapy for over two decades, yet poor solubility and non-specific delivery limit clinical effectiveness and can cause systemic toxicity. This study develops elastin-like polypeptide (ELP) nanocarriers modified with the tumor-targeting AP1 peptide to deliver paclitaxel. Paclitaxel conjugation to modified (A60) and unmodified (E60) ELPs yields stable, monodisperse micelles with distinct nanoparticle sizes and narrow DLS distributions. Enhanced IL-4 receptor–mediated binding and improved cytotoxicity are shown in SKOV-3 and OVCAR-3 cells, including 3D spheroid validation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeted-paclitaxel-delivery-in-ovarian-cancer-via-ap1-functionalized-elastin-like-polypeptide-nanocarriers-development-and-characterization/351114/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeted-paclitaxel-delivery-in-ovarian-cancer-via-ap1-functionalized-elastin-like-polypeptide-nanocarriers-development-and-characterization/351114.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address with paclitaxel in ovarian cancer?","Question",{"text":112,"@type":113},"Paclitaxel’s clinical use is limited by poor solubility and non-specific delivery, leading to systemic toxicity and inconsistent therapeutic outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are the AP1-functionalized ELP nanocarriers designed for targeted delivery?",{"text":117,"@type":113},"ELP nanocarriers are genetically engineered polymers, modified with the AP1 peptide that binds to the IL-4 receptor overexpressed in many cancers to enable active targeting.",{"name":119,"@type":110,"acceptedAnswer":120},"What findings demonstrate improved performance of A60-PTX versus E60-PTX?",{"text":121,"@type":113},"A60-PTX shows significantly enhanced cell binding (about 8.6-fold in SKOV-3 and about 2.7-fold in OVCAR-3), and superior cytotoxicity with lower IC50 values in both cell lines, confirmed in 3D spheroid models as well.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351114,1790673811,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Goel etal. BMC Cancer (2026) 26:284 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15615-0](https://doi.org/10.1186/s12885-026-15615-0)  \nRESEARCH Open Access  \nTargeted paclitaxel delivery in ovarian cancer via AP1-functionalized elastin-like polypeptide nanocarriers: development and characterization  \nRidhima Goel1, Shakeel Alvi2, Rashid Ali2, Pradeep Sharma3, Jayanta Bhattacharyya4, Vijaya Sarangthem5,6* and Thoudam Debraj Singh1*  \nAbstract  \nPaclitaxel has been a cornerstone of ovarian cancer chemotherapy for over two decades. However, its clinical application is constrained by poor solubility and non-specific delivery, resulting in systemic toxicity and inconsistent therapeutic outcomes. Nanotechnology-based drug delivery systems have emerged as a promising strategy to address these limitations. In this study, we employed elastin-like polypeptide (ELP) nanocarriers, precisely modified with the tumor-targeting AP1 peptide, to deliver paclitaxel in ovarian cancer. ELPs are biologically inspired, genetically engineered polymers that can form nano-sized structures with controlled physicochemical properties, facilitating passive tumor targeting. The integration of the AP1 peptide, which specifically binds to the IL-4 receptor overexpressed in numerous cancers, enables active targeting of these nanocarriers, complementing the passive delivery approach. This investigation focused on the synthesis and characterization of paclitaxel delivery vehicles based on modified (A60) and unmodified (E60) ELPs. Paclitaxel (PTX) was conjugated to ELPs via athiol–maleimide Michael-addition strategy. Both ELP-PTX formulations formed stable, monodisperse micelles, with A60-PTX nanoparticles measuring 28 ± 2.8 nm and E60-PTX nanoparticles measuring 46.8 ± 6.6 nm, as determined by TEM. DLS analysis further confirmed the narrow size distribution, evidenced by a single, narrow peak in the size distribution profile, indicating near homogeneity of the micellar population. In vitro binding analysis in SKOV-3 and OVCAR-3 ovarian cancer cells demonstrated significantly enhanced targeting capability with A60, exhibiting ~ 8.6-fold and ~ 2. 7-fold higher cell binding than E60, respectively. Consistently, A60-PTX demonstrated superior cytotoxicity, with ~ 2. 6-fold and ~ 1.4-fold lower IC50 values than E60-PTX in SKOV-3 (47 nM vs. 120 nM) and OVCAR-3 (45 nM vs. 62 nM), respectively. The relevance of the active targeting was further validated in agarosebased 3D spheroid models of the two cell lines with A60-PTX demonstrating approximately ~ 3-fold (SKOV-3) and~ 2. 5-fold (OVCAR-3) higher cytotoxicity compared to E60-PTX. Overall, this study highlights the potential of AP1-  \n*Correspondence: Vijaya Sarangthem  \ndevi [1703@gmail.com](1703@gmail.com)  \nThoudam Debraj Singh  \n[debraj.thoudam@gmail.com](debraj.thoudam@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/","cbCaidILoj55lkqA","https://ap.wps.com/l/cbCaidILoj55lkqA","pdf",7422993,15,"English","# Abstract\n# Introduction\n## Background: paclitaxel limitations in ovarian cancer\n## Nanotechnology-based drug delivery rationale\n## ELP platform and study direction","[{\"question\":\"What problem does the study address with paclitaxel in ovarian cancer?\",\"answer\":\"Paclitaxel’s clinical use is limited by poor solubility and non-specific delivery, leading to systemic toxicity and inconsistent therapeutic outcomes.\"},{\"question\":\"How are the AP1-functionalized ELP nanocarriers designed for targeted delivery?\",\"answer\":\"ELP nanocarriers are genetically engineered polymers, modified with the AP1 peptide that binds to the IL-4 receptor overexpressed in many cancers to enable active targeting.\"},{\"question\":\"What findings demonstrate improved performance of A60-PTX versus E60-PTX?\",\"answer\":\"A60-PTX shows significantly enhanced cell binding (about 8.6-fold in SKOV-3 and about 2.7-fold in OVCAR-3), and superior cytotoxicity with lower IC50 values in both cell lines, confirmed in 3D spheroid models as well.\"}]","Targeted paclitaxel delivery in ovarian cancer via AP1-functionalized elastin-like polypeptide nanocarriers - development and characterization | PDF",1790092673,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b2d6f9d089075a2d3bc8460742b49d3.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dae43c9b7f36e073127aad2aff51064c.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c618873f9026c40922dadf8e20447ad.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/778cfd08fd51c41142f0c14285cf675e.webp",980,1306]